Orthocell has today published its Quarterly Report for the period ended 31 March 2022.

Standout achievements for this Quarter include:

• Remplir™ nerve repair device receives Australian regulatory approval for introduction into the Australian nerve repair and regeneration market
• Application for inclusion of Remplir™ on the Prostheses List on track for submission in Q2 CY2022
• Final Remplir™ 24 month results of all patients in the nerve regeneration study on track for Q2 CY2022
• SignificantStriate+™ US market entry progress with sale of over 1,500 Striate+™ units achieved, and commencement of facility upgrade to enable scale up Striate+™ manufacturing capacity to >100,000 units per year
• Striate+™ distributor discussions progressed and the Company is in advanced discussions to engage its first US distributor and establish Striate+™ as the premium dental membrane
• The final data from the OrthoATI™ Phase 2a study on track for Q2 CY2022

 Click here to read today’s ASX release.

Orthocell’s Remplir™ device has gained Australian regulatory (Therapeutics Goods Administration) approval.

Read more

Orthocell’s Striate+™ dental membrane, which facilitates high quality and efficient bone and tissue repair, is gaining commercial momentum.

Read more

On International Day of Women In Science, we’re proud to shine a spotlight on Orthocell’s Quality Director, Monique Cannon.

Read more

Orthocell (ASX $OCC) has today published its Quarterly Report for the period ended 31 December 2021.

Read more

Orthocell (ASX $OCC) has today released positive clinical data for its OrthoATI™ tendon program, which shows that OrthoATI™ is statistically more effective than the current standard of care (corticosteroid injection) for treatment of rotator cuff tendinopathy with intrasubstance tendon tear.

Read more

Orthocell (ASX $OCC) has today released an update on its Ortho-ATI™ rotator cuff tendon study – the database is now locked and the Company is track to report the highly anticipated top line results in Q4 this calendar year.

This study was designed to assess the effectiveness of Ortho-ATI™, compared to corticosteroids, as a non-surgical treatment for a complex, hard-to-treat clinical problem.

Should the study meet its objectives, Orthocell is well positioned to deliver the first FDA approved injectable cell therapy in orthopaedics for the treatment of chronic tendon injuries in a rotator cuff market estimated at around US$2.8b per annum.

Click here to read today’s ASX release.